---
title: Real-world experience with TTFields in glioma patients with emphasis on therapy
  usage
date: '2025-01-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39839796/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250122171154&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Tumor Treating Fields (TTFields) has emerged as a significant adjunctive
  component in the treatment of high-grade gliomas following the EF-14 trial in 2017.
  The incorporation of TTFields, alongside cyclic temozolomide therapy, has demonstrated
  improved patient outcomes when the usage exceeds 18 h per day (75% usage). Post-hoc
  analysis of the EF-14 trial has demonstrated that therapy usage exceeding 90% is
  associated with an additional benefit, while rates above 50% have also proven effective
  ...
disable_comments: true
---
Tumor Treating Fields (TTFields) has emerged as a significant adjunctive component in the treatment of high-grade gliomas following the EF-14 trial in 2017. The incorporation of TTFields, alongside cyclic temozolomide therapy, has demonstrated improved patient outcomes when the usage exceeds 18 h per day (75% usage). Post-hoc analysis of the EF-14 trial has demonstrated that therapy usage exceeding 90% is associated with an additional benefit, while rates above 50% have also proven effective ...